Why the study?
Does a 24 h intravenous levosimendan infusion improve haemodynamic and neurohormonal outcomes compared to a 48 h dobutamine infusion in acute decompensated heart failure patients on beta-blockers?
Does a 24 h intravenous levosimendan infusion improve haemodynamic and neurohormonal outcomes compared to a 48 h dobutamine infusion in acute decompensated heart failure patients on beta-blockers?
In patients with acute decompensated heart failure on beta-blockers, a 24-hour levosimendan infusion provides superior haemodynamic and neurohormonal improvement at 48 hours compared to a 48-hour dobutamine infusion.
Supports preferring 24 h levosimendan over 48 h dobutamine in beta-blocked ADHF; extends randomized evidence for sustained haemodynamic benefit at 48 h.
A 24 h levosimendan infusion achieved haemodynamic and neurohormonal improvement that was at least comparable at 24 h and superior at 48 h to a 48 h dobutamine infusion.
No takes yet. Share an insight, caveat, or question.
Bergh et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: